Samir Ounzain, HAYA Therapeutics CEO
Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight
Eli Lilly is pairing up with a so-called “dark genome” biotech startup to hunt for a new generation of obesity and metabolic drugs.
The Indianapolis …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
